Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 14,300
-210 (-1.45%)
Apr 29, 2026, 10:30 AM KST
Hyundai Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3,517 | 15,050 | 9,481 | 7,852 | 9,241 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | - | Upgrade
|
| Revenue | 3,517 | 15,050 | 9,481 | 7,852 | 9,241 | Upgrade
|
| Revenue Growth (YoY) | -76.63% | 58.73% | 20.76% | -15.04% | -26.14% | Upgrade
|
| Cost of Revenue | 3,519 | 3,258 | 4,490 | 5,140 | 6,012 | Upgrade
|
| Gross Profit | -1.69 | 11,792 | 4,992 | 2,712 | 3,229 | Upgrade
|
| Selling, General & Admin | 9,896 | 7,598 | 7,846 | 6,542 | 6,647 | Upgrade
|
| Research & Development | 7,595 | 3,055 | 6,401 | 16,456 | 4,763 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | 328.42 | 489.85 | 1,228 | Upgrade
|
| Other Operating Expenses | 32.24 | 38.4 | 42.25 | 27.37 | 61.28 | Upgrade
|
| Operating Expenses | 18,159 | 10,959 | 14,795 | 29,023 | 12,519 | Upgrade
|
| Operating Income | -18,161 | 833.79 | -9,804 | -26,311 | -9,289 | Upgrade
|
| Interest Expense | -2,435 | -2,313 | -314.57 | -448.65 | -3,003 | Upgrade
|
| Interest & Investment Income | 1,326 | 210.7 | 669.19 | 536.69 | 291.71 | Upgrade
|
| Earnings From Equity Investments | -4,766 | -5,730 | - | 8,834 | 93.91 | Upgrade
|
| Currency Exchange Gain (Loss) | -38.16 | 3.73 | -68.67 | 48.15 | 20.39 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,978 | 94.13 | -335.47 | -182.82 | -404.46 | Upgrade
|
| EBT Excluding Unusual Items | -22,095 | -6,901 | -9,853 | -17,524 | -12,291 | Upgrade
|
| Gain (Loss) on Sale of Investments | -9.04 | 14.05 | 123.67 | 910.99 | - | Upgrade
|
| Asset Writedown | - | - | -4,769 | - | -7,517 | Upgrade
|
| Pretax Income | -22,105 | -6,887 | -14,498 | -16,613 | -19,808 | Upgrade
|
| Income Tax Expense | 3.89 | - | 1.04 | -805.47 | 243.5 | Upgrade
|
| Earnings From Continuing Operations | -22,108 | -6,887 | -14,499 | -15,807 | -20,051 | Upgrade
|
| Earnings From Discontinued Operations | -19.95 | -42.82 | - | - | - | Upgrade
|
| Net Income | -22,128 | -6,930 | -14,499 | -15,807 | -20,051 | Upgrade
|
| Net Income to Common | -22,128 | -6,930 | -14,499 | -15,807 | -20,051 | Upgrade
|
| Shares Outstanding (Basic) | 105,373 | 12,832 | 80 | 79 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 105,373 | 12,832 | 80 | 79 | 74 | Upgrade
|
| Shares Change (YoY) | 721.14% | 16030.92% | 1.04% | 6.64% | 2.79% | Upgrade
|
| EPS (Basic) | -0.21 | -0.54 | -182.26 | -200.77 | -271.58 | Upgrade
|
| EPS (Diluted) | -0.21 | -0.54 | -182.50 | -201.00 | -271.58 | Upgrade
|
| Free Cash Flow | -18,244 | 2,087 | -6,548 | -18,087 | -4,285 | Upgrade
|
| Free Cash Flow Per Share | -0.17 | 0.16 | -82.31 | -229.72 | -58.04 | Upgrade
|
| Gross Margin | -0.05% | 78.35% | 52.65% | 34.53% | 34.95% | Upgrade
|
| Operating Margin | -516.32% | 5.54% | -103.40% | -335.10% | -100.52% | Upgrade
|
| Profit Margin | -629.12% | -46.04% | -152.92% | -201.33% | -216.97% | Upgrade
|
| Free Cash Flow Margin | -518.69% | 13.87% | -69.06% | -230.36% | -46.37% | Upgrade
|
| EBITDA | -16,855 | 1,468 | -8,369 | -24,529 | -6,586 | Upgrade
|
| EBITDA Margin | - | 9.75% | -88.27% | - | -71.27% | Upgrade
|
| D&A For EBITDA | 1,306 | 633.82 | 1,435 | 1,782 | 2,703 | Upgrade
|
| EBIT | -18,161 | 833.79 | -9,804 | -26,311 | -9,289 | Upgrade
|
| EBIT Margin | - | 5.54% | -103.40% | - | -100.52% | Upgrade
|
| Advertising Expenses | 1,546 | 267.64 | 996.63 | 965.59 | 1,497 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.